SK Biopharmaceuticals CEO Donghoon Lee Purchases Additional 1,000 Company Shares

Just Two Weeks After Buying 2,000 Shares Last Month
Strategy Head Changho Yoo Also Purchases Additional 500 Shares

SK Biopharmaceuticals announced on September 15 that CEO Donghoon Lee has purchased an additional 1,000 shares of the company as a sign of confidence in the company’s value.

Lee Donghoon, CEO of SK Biopharmaceuticals, held a press conference regarding the introduction of "Opakalim" on the 26th of last month at the Westin Chosun in Jung-gu, Seoul. SK Biopharmaceuticals

Lee acquired the company shares at an average price of 78,800 won per share, resulting in a total purchase amount of approximately 79 million won. This additional share purchase comes about two weeks after he acquired 2,000 company shares on August 27.

On the same day as Lee’s purchase last month, Changho Yoo, head of strategy, also bought 500 company shares, and on this day, he acquired an additional 500 shares at an average price of 79,087 won per share.

According to SK Biopharmaceuticals, the fact that two key executives made additional share purchases within such a short period demonstrates their confidence in the company’s mid- to long-term growth strategy and corporate value, as well as their commitment to responsible management.

Last month, SK Biopharmaceuticals signed a licensing-in agreement for Opakalim (BHV-7000), a new epilepsy drug candidate, further building out its next-generation pipeline following cenobamate. Currently, Opakalim’s clinical development has been halted after receiving a partial clinical hold notification from the US Food and Drug Administration (FDA).

Opakalim is a selective potassium channel Kv7 activator currently being developed as a treatment for adult partial-onset seizures (POS). If the clinical and regulatory processes proceed as planned, SK Biopharmaceuticals could enter the US market as early as 2029.

This content was produced with the assistance of AI translation services.